Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service aneurysm & intracranial embolization cases in Connecticut: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 13% on average (82 state-years, 2020–2024): read it as a direction with a margin.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 2 | 55 | 46% |
| 2020 | 0 | 47 | 50% |
| 2021 | 1 | 81 | 53% |
| 2022 | 6 | 150 | 54% |
| 2023 | 6 | 176 | 57% |
| 2024 | 6 | 214 | 59% |
| 2025 from claims | – | 214 173–251 | 63% |
| 2026 forecast | – | 242 190–304 | 62% |
| 2027 forecast | – | 262 195–347 | 63% |
| 2028 forecast | – | 284 201–392 | 64% |
| 2029 forecast | – | 307 209–441 | 65% |
| 2030 forecast | – | 333 218–493 | 65% |
Aneurysm coiling and flow diversion, AVM and tumor embolization, intracranial stenting. Professional codes (what the surgeon bills): CPT 61624, 61635, 61630.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 100% of the cases CMS names in Connecticut; 5 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 100% inpatient hospital.
CMS rule changes ahead
From CMS’s OPPS/ASC final rules; the move measured on CMS’s claim summary, nationally, code by code. Medicare only, and not in the projected bars.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| New York | 25 | 1,148+12%/yr | +12%/yr | 0.6 | 0% | 1,980 in 2030+9.5%/yr |
| Pennsylvania | 29 | 803+20%/yr | +20%/yr | 0.6 | 0% | 1,470 in 2030+11%/yr |
| Massachusetts | 13 | 456+8%/yr | +8%/yr | 0.5 | 0% | 820 in 2030+10%/yr |
| New Jersey | 13 | 399+11%/yr | +11%/yr | 0.4 | 0% | 600 in 2030+7.1%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Stroke thrombectomy | 7 | 176+8.9%/yr | +8.9%/yr | 0.61.3× | 0% | 270 in 2030+7.2%/yr |
| CSF shunts | 1 | 129+5.9%/yr | +5.9%/yr | 0.42.0× | 0% | 250 in 2030+12%/yr |
Aneurysm & intracranial embolization in every state, and its device makers · Every procedure market in Connecticut · Every state · Compare with New York
Johnson & Johnson MedTech leads with 61% of company spending on these surgeons in 2025, +28 pts on 2024.
In 2025, 7 companies reported engagement with Connecticut’s surgeons worth $71K in consulting, speaking, meals and travel tied to these products, about $12K per surgeon billing it. Royalties are left out.
FDA, last 12 months: 12 clearances and approvals in the category, 4 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.